Edwards Lifesciences Corporation $EW Stake Lifted by Korea Investment CORP

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Korea Investment CORP increased its stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 37.5% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 647,275 shares of the medical research company's stock after acquiring an additional 176,625 shares during the period. Korea Investment CORP owned approximately 0.11% of Edwards Lifesciences worth $46,914,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of EW. Brighton Jones LLC acquired a new position in Edwards Lifesciences during the 4th quarter worth approximately $266,000. Bank Pictet & Cie Europe AG lifted its position in Edwards Lifesciences by 16.7% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 10,231 shares of the medical research company's stock worth $757,000 after acquiring an additional 1,463 shares in the last quarter. Townsquare Capital LLC lifted its position in Edwards Lifesciences by 24.8% during the 4th quarter. Townsquare Capital LLC now owns 6,501 shares of the medical research company's stock worth $481,000 after acquiring an additional 1,293 shares in the last quarter. CreativeOne Wealth LLC acquired a new position in Edwards Lifesciences during the 4th quarter worth approximately $201,000. Finally, GeoWealth Management LLC lifted its position in Edwards Lifesciences by 65.5% during the 4th quarter. GeoWealth Management LLC now owns 1,897 shares of the medical research company's stock worth $140,000 after acquiring an additional 751 shares in the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

EW has been the topic of several recent research reports. Argus raised Edwards Lifesciences to a "strong-buy" rating in a research report on Thursday, July 10th. Evercore ISI lifted their price objective on Edwards Lifesciences from $77.00 to $80.00 and gave the stock an "in-line" rating in a report on Friday, July 25th. Truist Financial lifted their price objective on Edwards Lifesciences from $81.00 to $82.00 and gave the stock a "hold" rating in a report on Friday, July 25th. Stifel Nicolaus lifted their price objective on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a "buy" rating in a report on Friday, July 25th. Finally, Mizuho lifted their price objective on Edwards Lifesciences from $87.00 to $95.00 and gave the stock an "outperform" rating in a report on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $85.90.

Edwards Lifesciences Stock Performance

Shares of NYSE EW traded up $0.5950 during trading on Friday, reaching $81.7550. The stock had a trading volume of 3,076,141 shares, compared to its average volume of 4,195,043. Edwards Lifesciences Corporation has a one year low of $64.00 and a one year high of $83.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The stock has a market cap of $48.00 billion, a PE ratio of 11.76, a P/E/G ratio of 3.95 and a beta of 1.08. The firm's 50 day moving average price is $77.58 and its two-hundred day moving average price is $74.72.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the previous year, the business earned $0.70 EPS. The business's quarterly revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, research analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Insider Activity

In other news, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the sale, the vice president directly owned 22,002 shares in the company, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the business's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares of the company's stock, valued at $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 24,584 shares of company stock worth $1,897,762. 0.34% of the stock is currently owned by insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.